Viatris Other Current Assets 2010-2024 | VTRS

Viatris other current assets from 2010 to 2024. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • Viatris other current assets for the quarter ending September 30, 2024 were $M, a 100% decline year-over-year.
  • Viatris other current assets for 2023 were $2.786B, a 1109.73% increase from 2022.
  • Viatris other current assets for 2022 were $0.23B, a INF% increase from 2021.
  • Viatris other current assets for 2021 were $0B, a NAN% decline from 2020.
Viatris Annual Other Current Assets
(Millions of US $)
2023 $2,786
2022 $230
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Viatris Quarterly Other Current Assets
(Millions of US $)
2024-09-30
2024-06-30 $1,609
2024-03-31 $2,520
2023-12-31 $2,786
2023-09-30 $427
2023-06-30 $175
2023-03-31 $198
2022-12-31 $230
2022-09-30 $1,426
2022-06-30 $1,465
2022-03-31 $1,337
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical Services $15.433B $15.427B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $95.766B 11.88
Cencora (COR) United States $49.023B 18.08
DiDi Global (DIDIY) China $23.330B 0.00
ICON (ICLR) Ireland $17.511B 15.60
Natera (NTRA) United States $16.712B 0.00
Avantor (AVTR) United States $14.831B 22.24
Revvity (RVTY) United States $14.647B 25.44
BioMerieux (BMXMF) France $12.894B 0.00
CochLear (CHEOY) Australia $12.739B 0.00
Solventum (SOLV) United States $12.214B 0.00
Medpace Holdings (MEDP) United States $11.215B 31.59
Charles River Laboratories (CRL) United States $11.042B 21.34
Doximity (DOCS) United States $10.778B 63.79
HealthEquity (HQY) United States $8.750B 47.49
Sonic Healthcare (SKHHY) Australia $8.450B 0.00
Bausch + Lomb (BLCO) Canada $6.881B 32.03
Life Times (LTH) United States $5.005B 33.12
Sotera Health (SHC) United States $4.402B 23.55
Organon (OGN) United States $4.012B 4.05
Surgery Partners (SGRY) United States $3.759B 42.85
BrightSpring Health Services (BTSG) United States $3.402B 72.37
PACS (PACS) United States $3.129B 0.00
Concentras Parent (CON) United States $2.579B 0.00
Alignment Healthcare (ALHC) United States $2.523B 0.00
Ardent Health Partners (ARDT) United States $2.446B 0.00
Premier (PINC) United States $2.301B 11.48
GeneDx Holdings (WGS) United States $2.113B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
GoodRx Holdings (GDRX) United States $1.783B 47.00
Teladoc Health (TDOC) United States $1.670B 0.00
Progyny (PGNY) United States $1.551B 29.62
Pediatrix Medical (MD) United States $1.331B 13.02
CareDx (CDNA) United States $1.251B 0.00
Establishment Labs Holdings (ESTA) $1.184B 0.00
AMN Healthcare Services Inc (AMN) United States $0.993B 6.72
Embecta (EMBC) United States $0.898B 5.99
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
InnovAge Holding (INNV) United States $0.778B 0.00
Agilon Health (AGL) United States $0.770B 0.00
SBC Medicals (SBC) United States $0.717B 0.00
Auna S.A (AUNA) Luxembourg $0.510B 0.00
Sonida Senior Living (SNDA) United States $0.442B 0.00
DocGo (DCGO) United States $0.426B 16.00
Enhabit (EHAB) United States $0.383B 33.09
COMPASS Pathways (CMPS) United Kingdom $0.346B 0.00
LifeMD (LFMD) United States $0.310B 0.00
ModivCare (MODV) United States $0.244B 13.24
Sera Prognostics (SERA) United States $0.242B 0.00
Beauty Health (SKIN) United States $0.211B 0.00
Nutex Health (NUTX) United States $0.204B 0.00
Biodesix (BDSX) United States $0.204B 0.00
MultiPlan (MPLN) United States $0.141B 0.00
Ascend Wellness Holdings (AAWH) United States $0.120B 0.00
So-Young (SY) China $0.073B 17.77
Singular Genomics Systems (OMIC) United States $0.057B 0.00
Harvard Apparatus Regenerative Technology (HRGN) United States $0.054B 0.00
OncoCyte (OCX) United States $0.051B 0.00
NeueHealth (NEUE) United States $0.042B 1.12
Co-Diagnostics (CODX) United States $0.037B 0.00
Pheton Holdings (PTHL) China $0.029B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.027B 0.00
IceCure Medical (ICCM) Israel $0.027B 0.00
Oncology Institute (TOI) United States $0.022B 0.00
SeaStar Medical Holding (ICU) United States $0.012B 0.00
XWELL (XWEL) United States $0.009B 0.00
Intelligent Bio Solutions (INBS) United States $0.009B 0.00
BioNexus Gene Lab (BGLC) $0.006B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00